FDA Panel Starts to Tackle Avandia Safety

(MedPage Today) -- SILVER SPRING, Md. -- A controversial study of the cardiovascular safety of one-time diabetes blockbuster rosiglitazone (Avandia) has proven difficult for FDA and independent reviewers to reanalyze, multiple speakers said here Wednesday.
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news